

TRANSMISSION REPORT

#21

(TUE) MAR 17 1998 15:04

WARNER-LAMBERT CO.

DOCUMENT #	3560555-625
TIME STORED	03. 17 15:02
TIME SENT	03. 17 15:03
DURATION	53"
DESTINATION	703 308 6916
DST. TEL#	917033086916
MODE	ECM
PAGE (S)	2PAGE (S)
RESULT	OK
DEPARTMENT	



Corporate Legal Division

2800 Plymouth Road
Ann Arbor, MI 48105
FAX: (734) 622-1553

To: Karin Tyson	Re: Interim Patent Extension
Fax: (703) 308-6916	Date: March 17, 1998
From: Todd M. Crissey Counsel, Patents	Pages (including cover): 2
Phone: (734) 622-7530	
If this fax is not received clearly, call (734) 622-5026	

NOTICE: This facsimile is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this facsimile is not the intended recipient, or an employee or agent responsible for delivering the facsimile to the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of the communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately at the telephone number(s) listed above and return the original facsimile to us at the above address by US mail, the cost of which will be reimbursed. Thank you.

Please refer to attached letter.

**WARNER
LAMBERT**

Corporate Legal Division

2800 Plymouth Road
Ann Arbor, MI 48105

FAX: (734) 622-1553

Todd M. Crissey
(734) 622-7530

March 17, 1998

Via facsimile to (703) 308-6916

Ms. Karin Tyson
Special Program Law Office
U.S. Patent and Trademark office
Washington, D.C. 20231

Dear Ms. Tyson:

Thank you for your assistance this morning with regard to updating us on the present status of our Application For Extension of Patent Term Under 35 U.S.C. § 156 for U.S. Patent Number 4,260,769, which covers the approved product Cerebyx® (fosphenytoin sodium).

I understand that our Application for Extension of Patent Term Under 35 U.S.C. § 156 is currently in the process of being considered and approved. However, U.S. Patent Number 4,260,769 will expire on April 7, 1998, and it does not appear that the extension will be granted by then.

As we discussed, we would like to obtain an interim extension for the above-referenced patent in accordance with 37 C.F.R. § 1.760. Please consider this letter a request for an interim extension under 37 C.F.R. § 1.760.

Thank you for your help.

Very truly yours,



Todd M. Crissey
Counsel,
Pharmaceutical Patents
Reg. No. 37,807